Medications with Generic Name Beginning ‘D’

Page 1 of 580 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

Dabigatran Etexilate

Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the…

Ascend Laboratories, LLC12 March 2020

PRADAXA (Dabigatran Etexilate Mesylate)

PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. PRADAXA is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with…

Rebel Distributors Corp23 November 2010

Pradaxa (Dabigatran Etexilate Mesylate)

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep…

Bryant Ranch Prepack1 October 2019

Pradaxa (Dabigatran Etexilate Mesylate)

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep…

A-S Medication Solutions18 January 2020

Pradaxa (Dabigatran Etexilate Mesylate)

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep…

Boehringer Ingelheim Pharmaceuticals Inc.23 January 2020

Page 1 of 580 1 2 3 4 5 … 10 15 20 25 30 … » Last Page »

FDA Medwatch

Acella Pharmaceuticals, LLC Issues Voluntary Nationwide Recall of Certain Lots of NP Thyroid® (Thyroid Tablets, USP) Due to Super Potency
Thu, 21 May 2020. Acella Pharmaceuticals, LLC is voluntarily recalling a total of 13 lots of 30-mg, 60-mg and 90-mg NP Thyroid® (thyroid tablets, USP) to the consumer level. The products are being recalled because our testing has found these lots to be superpotent…
Biota Biosciences Issues Voluntary Nationwide Recall of Cannabidiol (CBD) Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables Because They Were Marketed Without FDA Approval
Tue, 19 May 2020. Biota Biosciences is voluntarily recalling the following lots in the table below of Cannabidiol (CBD) Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables to the customer level.

MedLibrary.org

Medication Sections

RSS Feeds

About

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.